(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China...
Stats | |
---|---|
今日成交量 | 15.90M |
平均成交量 | 11.87M |
市值 | 28.78B |
EPS | CNY0.227 ( 2023-10-30 ) |
下一个收益日期 | ( CNY0 ) 2024-05-16 |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | 113.42 |
ATR14 | CNY0.0480 (0.10%) |
音量 相关性
Gan & Lee 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Gan & Lee 相关性 - 货币/商品
Gan & Lee 财务报表
Annual | 2023 |
营收: | CNY2.58B |
毛利润: | CNY1.79B (69.20 %) |
EPS: | CNY0.600 |
FY | 2023 |
营收: | CNY2.58B |
毛利润: | CNY1.79B (69.20 %) |
EPS: | CNY0.600 |
FY | 2022 |
营收: | CNY1.71B |
毛利润: | CNY1.31B (76.30 %) |
EPS: | CNY-0.780 |
FY | 2021 |
营收: | CNY3.61B |
毛利润: | CNY3.22B (89.03 %) |
EPS: | CNY2.59 |
Financial Reports:
No articles found.
Gan & Lee
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。